OBI Pharma Past Earnings Performance
Past criteria checks 0/6
OBI Pharma's earnings have been declining at an average annual rate of -0.3%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been declining at an average rate of 5.3% per year.
Key information
-0.3%
Earnings growth rate
4.5%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | -5.3% |
| Return on equity | -59.0% |
| Net Margin | -3,712.8% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How OBI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 58 | -2,155 | 328 | 1,817 |
| 31 Mar 24 | 49 | -1,205 | 327 | 1,821 |
| 31 Dec 23 | 42 | -1,046 | 319 | 1,697 |
| 30 Sep 23 | 24 | -1,100 | 321 | 1,853 |
| 30 Jun 23 | 13 | -920 | 305 | 1,866 |
| 31 Mar 23 | 5 | -1,672 | 301 | 1,799 |
| 31 Dec 22 | 5 | -1,614 | 310 | 1,773 |
| 30 Sep 22 | 7 | -1,595 | 278 | 1,767 |
| 30 Jun 22 | 8 | -1,532 | 268 | 1,577 |
| 31 Mar 22 | 16 | -1,605 | 262 | 1,547 |
| 31 Dec 21 | 19 | -1,531 | 241 | 1,450 |
| 30 Sep 21 | 95 | -1,341 | 269 | 1,262 |
| 30 Jun 21 | 94 | -1,397 | 286 | 1,242 |
| 31 Mar 21 | 145 | -1,295 | 288 | 1,185 |
| 31 Dec 20 | 141 | -1,378 | 290 | 1,310 |
| 30 Sep 20 | 67 | -1,519 | 322 | 1,403 |
| 30 Jun 20 | 66 | -1,460 | 294 | 1,378 |
| 31 Mar 20 | 6 | -1,508 | 310 | 1,403 |
| 31 Dec 19 | 6 | -1,407 | 313 | 1,257 |
| 30 Sep 19 | 1 | -1,301 | 321 | 1,137 |
| 30 Jun 19 | 1 | -1,395 | 325 | 1,236 |
| 31 Mar 19 | 1 | -1,173 | 306 | 1,162 |
| 31 Dec 18 | 13 | -1,222 | 309 | 1,127 |
| 30 Sep 18 | 13 | -1,177 | 291 | 1,020 |
| 30 Jun 18 | 13 | -1,098 | 320 | 897 |
| 31 Mar 18 | 13 | -1,238 | 343 | 868 |
| 31 Dec 17 | 0 | -1,379 | 341 | 849 |
| 30 Sep 17 | 0 | -1,298 | 331 | 903 |
| 30 Jun 17 | 0 | -1,329 | 326 | 873 |
| 31 Mar 17 | 92 | -1,166 | 330 | 800 |
| 31 Dec 16 | 92 | -1,110 | 345 | 859 |
| 30 Sep 16 | 92 | -1,093 | 359 | 755 |
| 30 Jun 16 | 92 | -860 | 369 | 664 |
| 31 Mar 16 | 0 | -916 | 341 | 628 |
| 31 Dec 15 | 0 | -941 | 415 | 648 |
| 30 Sep 15 | 0 | -868 | 343 | 645 |
| 30 Jun 15 | 0 | -885 | 351 | 568 |
| 31 Mar 15 | 0 | -925 | 322 | 641 |
| 31 Dec 14 | 0 | -667 | 227 | 485 |
| 30 Sep 14 | 0 | -617 | 243 | 413 |
| 30 Jun 14 | 0 | -565 | 181 | 418 |
| 31 Mar 14 | 0 | -453 | 161 | 320 |
| 31 Dec 13 | 0 | -439 | 122 | 345 |
Quality Earnings: 4174 is currently unprofitable.
Growing Profit Margin: 4174 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4174 is unprofitable, and losses have increased over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare 4174's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4174 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (33.2%).
Return on Equity
High ROE: 4174 has a negative Return on Equity (-59.02%), as it is currently unprofitable.